Key result
Newer HER2-directed therapies show no difference in cardiotoxicity risk compared to conventional trastuzumab regimens.
Why the study?
The incidence and comparative risk of cardiotoxicity associated with newer HER2-targeted therapies compared with conventional trastuzumab-based regimens were not established across drug classes, clinical subgroups, and monitoring strategies.
Does the use of newer HER2-directed therapies increase the risk of cardiotoxicity compared to conventional trastuzumab-based regimens in adult patients with HER2-expressing breast cancer?
Meta-Analysis (n=35,984)
Does the use of newer HER2-directed therapies increase the risk of cardiotoxicity compared to conventional trastuzumab-based regimens in adult patients with HER2-expressing breast cancer?
Newer HER2-directed therapies demonstrate a low overall incidence of cardiotoxicity, primarily LVEF decline, with no significant excess risk compared to conventional trastuzumab-based regimens.
Comparable cardiotoxicity risk with newer HER2 therapies; confirms safety equivalence to trastuzumab in randomized evidence.
Purpose This systematic review and meta-analysis aimed to estimate the incidence and comparative risk of cardiotoxicity associated with newer HER2-targeted therapies compared with conventional trastuzumab-based regimens. It also evaluates the differences across drug classes, clinical subgroups, and monitoring strategies. Materials and Methods PubMed, Embase, CENTRAL, and Scopus were searched (2005-2025) for randomized controlled trials (RCTs) and prospective studies reporting cardiac outcomes with HER2-directed therapies. Pooled cardiotoxicity incidence was calculated from single-arm studies and intervention arms of RCTs and risk ratios (RRs) from RCTs using random-effects models. Subgroup analyses were performed by drug class, anthracycline exposure, HER2 category, age, and cardiac monitoring frequency. Certainty of evidence was assessed using GRADE. Results Fifty-eight studies (35,984 patients) were included. Pooled cardiotoxicity incidence was 5.08% (95% CI, 3.37 to 7.58) with left ventricular ejection fraction (LVEF) decline in 4.68% patients, and other cardiac events were each reported in <1% patients. Across 32 RCTs, no significant difference in cardiotoxicity was observed between newer HER2-directed therapies and trastuzumab-based comparator regimens (including trastuzumab monotherapy or trastuzumab combined with chemotherapy, with or without pertuzumab) (RR, 0.97; 95% CI, 0.73 to 1.29). Subgroup analyses showed variability across study characteristics, with higher incidence observed in studies using more frequent cardiac monitoring (8.15%; 95% CI, 3.13 to 19.61%, P > 0.05). Conclusion Newer HER2-directed therapies demonstrate low cardiotoxicity, with rare serious events and no evidence of excess risk compared with conventional trastuzumab-based regimens. These findings support cardiac safety but suggest the need for standardized monitoring and uniform cardiotoxicity definitions.
No takes yet. Share an insight, caveat, or question.
Sundaramoorthy et al. (2026) conducted a meta-analysis in Breast cancer receiving HER2-directed therapies (n=35,984). Newer HER2-directed therapies (ADCs, monoclonal antibodies, TKIs) vs. Conventional trastuzumab-based regimens (trastuzumab monotherapy or combined with chemotherapy, with/without pertuzumab) was evaluated on Comparative risk of cardiotoxicity (RR 0.97, 95% CI 0.73-1.29, p=0.82). Newer HER2-directed therapies demonstrated no significant difference in the risk of cardiotoxicity compared to conventional trastuzumab-based comparator regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: